Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Preferred Shares (2023 - 2025)

Historic Preferred Shares for SAB Biotherapeutics (SABS) over the last 3 years, with Q3 2025 value amounting to $64.0.

  • SAB Biotherapeutics' Preferred Shares rose 118000.0% to $64.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $64.0, marking a year-over-year increase of 118000.0%. This contributed to the annual value of $5.0 for FY2024, which is 0.0% changed from last year.
  • As of Q3 2025, SAB Biotherapeutics' Preferred Shares stood at $64.0, which was up 118000.0% from $5.0 recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Preferred Shares peaked at $64.0 during Q3 2025, and registered a low of $5.0 during Q4 2023.
  • Its 3-year average for Preferred Shares is $12.38, with a median of $5.0 in 2023.
  • As far as peak fluctuations go, SAB Biotherapeutics' Preferred Shares changed by 0.0% in 2024, and later soared by 118000.0% in 2025.
  • Over the past 3 years, SAB Biotherapeutics' Preferred Shares (Quarter) stood at $5.0 in 2023, then changed by 0.0% to $5.0 in 2024, then surged by 1180.0% to $64.0 in 2025.
  • Its Preferred Shares stands at $64.0 for Q3 2025, versus $5.0 for Q2 2025 and $5.0 for Q1 2025.